Our findings regarding CD8+TILs exhaustion status could not only help predict the survival risk of patients with AITL but also facilitate further mechanistic studies and are valuable in guiding immunotherapy strategies. This evidence concerns the gene CD8A and angioimmunoblastic T-cell lymphoma.